Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
Altamira Therapeutics Ltd. - Common Shares (CYTO)
Company Research
Source: GlobeNewswire
Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked warrants Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the closing of its previously announced public offering of an aggregate of 5,555,556 common shares (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 5,555,556 common shares and Series A-2 common warrants to purchase up to 5,555,556 common shares, at a combined public offering price of $0.72 per share (or per pre-funded warrant in lieu thereof) and accompanying Series A-1 common warrant and Series A-2 common warrant. The Series A-1 common warrants have an exercise price of $0.72 per share, are immediately exercisable upon issuance and
Show less
Read more
Impact Snapshot
Event Time:
CYTO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTO alerts
High impacting Altamira Therapeutics Ltd. - Common Shares news events
Weekly update
A roundup of the hottest topics
CYTO
News
- Altamira Therapeutics receives Nasdaq non-compliance letter [Seeking Alpha]Seeking Alpha
- Altamira Therapeutics Provides Update on Nasdaq ListingGlobeNewswire
- Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal SprayGlobeNewswire
- Altamira Therapeutics Provides Business Update and First Half 2024 Financial ResultsGlobeNewswire
- Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia [Yahoo! Finance]Yahoo! Finance
CYTO
Sec Filings
- 11/14/24 - Form SC
- 10/4/24 - Form 6-K
- 9/24/24 - Form 6-K
- CYTO's page on the SEC website